Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Xeris Pharmaceuticals Inc / Equity Bottom-Up

<ul><li>Xeris Biopharma Holdings has suddenly become one of the more intriguing names in pharmaceutical M&A after Lundbeck expressed interest in acquiring the commercial-stage drugmaker, even as Xeris maintained that it is not for sale.</li><li>The timing is notable because Xeris is not facing the typical profile of a pressured takeover candidate.</li><li>Its commercial portfolio is expanding rapidly, Recorlev has emerged as the company’s principal growth engine, Gvoke has returned to sequential growth, and Keveyis continues to generate durable rare-disease revenue.</li></ul>

Xeris Biopharma Holdings has suddenly become one of the more intriguing names in pharmaceutical M&A after Lundbeck expressed interest in acquiring the commercial-stage drugmaker, even as Xeris maintained that it is not for sale.The timing is notable because Xeris is not facing the typical profile of a pressured takeover candidate.Its commercial portfolio is expanding rapidly, Recorlev has emerged as the company’s principal growth engine, Gvoke has returned to sequential growth, and Keveyis continues to generate durable rare-disease revenue.

Xeris Says It’s “Not For Sale”—So Why Is Lundbeck Circling?

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Xeris Pharmaceuticals is a commercial-stage biopharmaceutical company with a diversified portfolio of three approved products: Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous Cushing's syndrome.</li>
  <li>The company's growth is primarily driven by the strong commercial performance of Recorlev, which has seen significant revenue acceleration.</li>
  <li>Xeris has a promising late-stage pipeline candidate, XP-8121, a once-weekly subcutaneous injection for hypothyroidism, which has the potential to be a major value driver in the long term.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Xeris Pharmaceuticals is a commercial-stage biopharmaceutical company with a diversified portfolio of three approved products: Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous Cushing's syndrome.
  The company's growth is primarily driven by the strong commercial performance of Recorlev, which has seen significant revenue acceleration.
  Xeris has a promising late-stage pipeline candidate, XP-8121, a once-weekly subcutaneous injection for hypothyroidism, which has the potential to be a major value driver in the long term.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Xeris Pharmaceuticals Inc (XERS US) - Aug 2026

United States

Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens, and infusion pumps to treat endocrine and metabolic diseases. Xeris Pharmaceuticals serves patients in the State of Illinois.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Xeris Pharmaceuticals Inc (XERS US)

Xeris Says It’s “Not For Sale”—So Why Is Lundbeck Circling?

Xeris Biopharma Holdings has suddenly become one of the more intriguing names in pharmaceutical M&A after Lundbeck expressed interest in...

Baptista Research

Primer: Xeris Pharmaceuticals Inc (XERS US) - Aug 2026

Xeris Pharmaceuticals is a commercial-stage biopharmaceutical company with a diversified portfolio of three approved products: Gvoke for severe...

αSK Primers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)